The results of the
TRINITY study on the use in a single inhaler of the 3 types of
inhalation medications used in COPD (Corticoid, Beta 2-agonist and
muscarinic receptor antagonist) were published in the LANCET journal and
revealed a 20% decrease in the number of Exacerbations. There
is still no such inhaler of this type authorized for marketing, which
is expected to happen next year and will change how patients with more
severe COPD and which causes more symptoms are treated.
The authors compared this drug with one of the most used currently and also with the 3 components, using 2 different inhalers.